|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4307-4312
RAPID COMMUNICATION
The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines
By
Andrea König,
Gary K. Schwartz,
Ramzi M. Mohammad,
Ayad Al-Katib, and
Janice L. Gabrilove
From The Molecular Therapeutics Program, the Sloan-Kettering Institute; the Department of Medicine, the Division of Hematology-Oncology and the Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center; New York, NY; and the Division of Hematology and Oncology, the Department of Internal Medicine, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI.
 |
ABSTRACT |
Flavopiridol is a novel, potent inhibitor of cyclin-dependent kinases (CDK). This synthetic flavone has been reported to exhibit antitumor activity in murine and human tumor cell lines in vitro and in vivo and is currently undergoing clinical phase I evaluation. In the present study, 1 Epstein-Barr virus (EBV)-transformed B-prolymphocytic cell line (JVM-2), 1 EBV-transformed B-CLL cell line (I83CLL), and 1 non-EBV transformed B-CLL cell line (WSU-CLL) were used as targets. Treatment of the cells with flavopiridol (100 nmol/L to 400 nmol/L) led to a marked dose- and time-dependent inhibition of cell growth and survival as determined using trypan blue exclusion. Morphologic analysis showed characteristic apoptotic changes such as chromatin condensation and fragmentation, membrane blebbing, and formation of apoptotic bodies. Furthermore, quantitative assessment of apoptosis-associated DNA strand breaks by in situ TdT labeling showed that a significant number of flavopiridol-treated cells underwent apoptosis. These cellular effects were associated with a significant decrease in bcl-2 expression as observed by Northern and Western blotting. The results showed that flavopiridol downregulates bcl-2 mRNA and bcl-2 protein expression within 24 hours. Genistein and quercetin, two flavonoids that do not inhibit CDKs, did not affect bcl-2 expression. These data suggest an additional mechanism of action of this new flavone which might be useful as an agent in the treatment of chronic lymphoid malignancies.
| |
INTRODUCTION |
FLAVONOIDS SUCH as genistein or quercetin have been shown to inhibit tumor cell growth.1 Flavopiridol is a new synthetic flavone that has been demonstrated to have growth inhibitory activity in vitro and in vivo in numerous human tumor cell lines and xenograft models.2-4 The agent has been found to induce a blockade of cell-cycle progression at G1 or G2 interfaces, in association with direct inhibition of CDK2, CDK4, and CDK1.5,6 Interestingly, flavopiridol has been shown to enhance the cytotoxic effect of conventional chemotherapeutic agents in gastric and breast cancer cell lines.7 A phase I clinical trial has recently been performed to evaluate the potential antineoplastic effect of this compound.8
Chronic lymphocytic leukemia (CLL), the most frequent type of adult leukemia in Western countries, is a malignant disorder characterized by the progressive accumulation of clonally derived, CD5+ , CD19+ B lymphocytes.9 It has been suggested that prolonged life span, due to dysregulation of apoptosis, is a major factor contributing to the delayed senescence of these transformed lymphocytes.10 In this regard, the proto-oncogene bcl-2, which delays apoptosis, has been documented to be highly expressed in most B-CLL,11 although a translocation of the gene occurs infrequently in this disease.12 Overexpression of bcl-2 has been associated with resistance to chemotherapy and inhibition of apoptosis.13,14
In this study we investigated the ability of flavopiridol to induce apoptosis in chronic lymphoid malignancies of the B-cell type including CLL and prolymphocytic leukemia (PLL). In addition, we show for the first time that the growth inhibition and induction of apoptosis observed in CLL cells exposed to flavopiridol is associated with the ability of this agent to downregulate the expression of bcl-2 mRNA and protein.
| |
MATERIALS AND METHODS |
Reagents.
Flavopiridol (L 86-8275, [(-) cis-5,7-dihydroxy-2-(2-chlorophenyl ) - 8 - ;ob 4 - ( 3 - hydroxy - 1 - methyl ) - piperidinyl ;cb - 4H - 1 - ben -zopyran-4-one]) was dissolved in sterile H2O at a stock concentration of 100 µmol/L and stored at -20°C. Serial dilutions (200 to 800 nmol/L) were made in medium. The agent was kindly provided by Dr Edward A. Sausville (National Cancer Institute, NIH, Bethesda, MD). Genistein and quercetin (both from Calbiochem, La Jolla, CA) were dissolved in dimethyl sulfoxide (DMSO) at stock solutions of 10 mmol/L. Further dilutions (10 to 50 µmol/L) were set up in media. Fludarabine des-phosphate (FAra, 9- -D-arabinosyl-2-fluoroadenine) (Sigma, St Louis, OH) was dissolved in 100% DMSO for a stock solution of 10 mmol/L. It was further diluted in medium at final concentrations of 1 to 5 µmol/L.
Cell lines.
The well-characterized permanent human B-cell leukemia cell line JVM-215 was originally established from the peripheral blood of a patient with B-prolymphocytic leukemia (PLL) by Epstein-Barr virus (EBV)-immortalization. The human chronic B-cell leukemia cell line I83CLL was derived from the peripheral blood of a patient with B-cell chronic lymphocytic leukemia (B-CLL) by EBV-immortalization.16 The human EBV- chronic B-cell leukemia cell line WSU-CLL was established from a patient with advanced B-CLL17 and the human promyelocytic cell line HL-60 (used as a positive control for bcl-2 expression) were cultured in RPMI 1640, supplemented with 1% penicillin/streptomycin, 1 mmol/L L-glutamine (GIBCO-BRL, Grand Island, NY), 10% heat-inactivated fetal bovine serum (FBS) (GIBCO-BRL) at 37°C, 5% CO2 in air.
Viability and cell growth.
Loss of cell viability and cell growth as measured by trypan blue (GIBCO-BRL) exclusion were assessed at specified time points in suspension cultures. At selected time points, samples, performed in triplicate, were collected and evaluated.
Nonradioactive Northern blot analysis.
Total cellular RNA (10 µg/lane) was size-fractionated by electrophoresis in a 1.2% agarose gel containing 0.7 mol/L formaldehyde, transferred to nylon membranes (Hybond N; Amersham, Arlington Heights, IL) by capillary suction overnight, and crosslinked by UV-light (Stratalinker; Stratagene, La Jolla, CA). The cDNA probe for bcl-2 (generously provided by Dr Andrew Zelenetz, Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY), a 410-bp EcoRI fragment in pCR II vector (TA cloning vector; Invitrogen, San Diego, CA), digested with BamHI, was labeled with digoxygenin-UTP (DIG-UTP) (Boehringer Mannheim, Indianapolis, IN) by in vitro transcription with respect to T7 RNA-polymerase. The cDNA probe for glyceraldehyde-phosphate-dehydrogenase (GAPDH), a 1,270-bp insert in pBS KS+ (American Type Culture Collection [ATCC], Rockville, MD), was linearized with EcoRI and labeled with DIG-UTP by in vitro transcription with respect to T7 RNA-polymerase. Hybridization was performed as previously described.18 Detection was accomplished by chemiluminescent reaction according to the Genius System (Boehringer Mannheim) as previously described.18
View larger version (38K):
[in this window]
[in a new window]
| Fig 1.
Effect of flavopiridol on the viability and cell growth of the B-CLL cell lines WSU-CLL, 183CLL, and JVM-2. 1.5 × 105 cells/mL were incubated in the presence of various concentrations of flavopiridol (100, 200, 400 nmol/L) over a time period of 72 hours. Untreated cells were used as control. Mean viability was assessed using trypan blue dye exclusion. A representative experiment (performed in triplicate) is shown.
|
|
In situ TdT assay.
The in situ terminal deoxynucleotidyl transferase (TdT) assay was performed as previously described.19 Briefly, aliquots of cells were collected from liquid culture centrifuged, and fixed in 0.3% buffered formaldehyde (pH 7.5). After washing with phosphate-buffered saline (PBS), cells were resuspended in 70% ethanol (-20°C) and stored at -20°C. Following rehydration with PBS, the cells were resuspended in 50 µL cacodylate buffer containing 0.2 mol/L potassium cacodylate, 2.5 mmol/L Tris-HCl (pH 6.6), 2.5 mmol/L cobalt chloride (CoCl2 ), 0.25 mg/mL bovine serum albumin, 7.5 U of terminal deoxynucleotidyl transferase (TdT), and 0.5 nmol/L biotinylated deoxyuracil-triphosphphate (b-dUTP) (all reagents from Boehringer Mannheim). After an incubation period in this solution for 30 minutes at 37°C, cells were washed with PBS and resuspended in 100 µL of a solution containing 4 × salt saturated citrate (SSC), 25 µg/mL avidin-fluorescein-isothiocyanate (avidin-FITC; Boehringer Mannheim), 0.1% Triton X-100, and 5% wt/vol nonfat dry milk, and incubated for 30 minutes in the dark at room temperature. Cells were washed with PBS containing 0.1% Triton X-100 and resuspended in 0.5 mL PBS containing 5 µg/mL propidium iodide (Sigma) and 0.1% RNAse A (Sigma). Green fluorescence detecting FITC levels and red fluorescence measuring propidium iodide content of individual cells were quantified on a FACStar (Becton Dickinson, Franklin Lakes, NJ), and data from 2 × 104 cells were collected and used for analysis.
Western blot analysis.
Cells were lysed in a lysis buffer containing 20 mmol/L Tris HCl, 1 mmol/L EGTA, 50 µmol/L NaVO4 , 50 mmol/L NaF, 0.01 U/mL aprotinin, 10 µg/mL leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride (PMSF) (all from Sigma). The lysates were then sonicated using a ultrasonic homogenizer (4710 series; Cole Parmer Instruments, Chicago, IL), centrifuged at 7,500g in a microfuge (Sorvall Instruments, Wilmington, DE), and the protein content of the lysates was determined (BioRad Protein Assay Kit I, Melville, NY) at 595 nm with a bovine serum albumin (BSA) standard. Sample buffer containing 10% glycerol, 0.4% sodium dodecyl sulfate (SDS), 0.3% bromphenol blue, 0.2% pyronin Y, in 1 × stacking buffer (Tris base 0.5 mol/L, 0.8% SDS), 20% 2-mercaptoethanol, was added to the cell lysates that subsequently were heat-denaturated at 95°C for 3 minutes. 10 µg/lane of protein was loaded on a SDS-polyacrylamide gel containing 12.5% polyacrylamide, and size-fractionated by electrophoresis. Proteins were electroblotted onto Immobilon-P PVDF transfer membrane (Millipore, Bedford, MA) and immunostained with a mouse-antihuman monoclonal bcl-2 antibody (1:5,000; Dako, Carpinteria, CA). Bound antibody was detected using the ECL chemiluminescence detection system (Amersham, Arlington Heights, IL). Protein bands were quantified by computer densitometry.
View larger version (48K):
[in this window]
[in a new window]
| Fig 2.
Detection of apoptosis-associated DNA strand-breaks by in situ terminal deoxynucleotidyl transferase assay (TdT-assay) in WSU-CLL and I83CLL cells. The cells were either untreated (CTRL) or exposed flavopiridol (200 nmol/L, 400 nmol/L) for 24 hours, respectively. The dots represent the distribution of individual cells with respect to their b-dUTP incorporation and DNA content. The degree of b-dUTP complexes correlated with DNA strand-breaks per cell.
|
|
| |
RESULTS |
Flavopiridol decreases viability and arrests cell growth in CLL cell lines.
JVM-2, I83CLL, and WSU-CLL cells were used as targets to investigate the effect of flavopiridol on the growth and survival. A significant decrease in cell viability was observed over time in all of the cells exposed to varying concentrations of flavopiridol. A difference in the kinetics of the response to flavopiridol varied among the three cell lines. In this regard, a 50% reduction in cell viability following exposure to 400 nmol/L flavopiridol was observed after 24 hours (I83CLL), 30 hours (WSU-CLL), and 40 hours (JVM-2), respectively (Fig 1A, C, and E).
Exposure of JVM-2, I83CLL, and WSU-CLL cells to flavopiridol resulted in a significant dose-dependent inhibition of cell growth. A dose of 400 nmol/L was required in WSU-CLL cells to induce growth arrest, whereas a concentration as low as 200 nmol/L led to comparable effects in JVM-2 and I83CLL cells.
Induction of apoptosis by flavopiridol.
Morphologic analysis showed characteristic apoptotic changes such as chromatin condensation and fragmentation, membrane blebbing, and formation of apoptotic bodies in all three cell line targets after treatment with flavopiridol (200 to 400 nmol/L) (data not shown).
I83CLL and WSU-CLL cells were treated with flavopiridol and examined for apoptosis-associated DNA strand breaks using the in situ terminal deoxynucleotidyl transferase assay (TdT-assay). The intensity of labeling of apoptotic cells with biotinylated dUTP correlated with the number of DNA strand breaks per cell. The data showed that a significant number of cells exposed to flavopiridol underwent apoptosis. Treatment of WSU-CLL cells with flavopiridol (200 and 400 nmol/L) for 24 hours resulted in 9.59% and 48.67%, respectively, to be apoptotic versus control cells with 0.46% apoptosis. A similar dose-dependent response could be observed in I83CLL cells with 21% (200 nmol/L) and 53.9% (400 nmol/L) apoptotic cells as compared with 2.1% apoptosis in control cells observed at 24 hours after exposure (Fig 2).
Flavopiridol decreases the expression of bcl-2.
To investigate the potential effect of flavopiridol on bcl-2, we examined the expression on both mRNA and protein after a 24-hour exposure to this agent. Northern (data shown for JVM-2 cells in Fig 3) and Western blot analysis (data shown for WSU-CLL and I83CLL cells in Fig 4A) demonstrated a concentration-dependent decrease of bcl-2 expression in all three cell lines. The sensitivity to flavopiridol paralleled that observed for cell growth and loss of viability among the cell lines: A concentration of 200 and 400 nmol/L was observed to be potent in I83CLL cells whereas similar effects in WSU-CLL cells were obtained with 400 or 800 nmol/L (Fig 4A). To further evaluate whether other flavonoids such as genistein or quercetin also affect the expression of bcl-2 protein, WSU-CLL cells were exposed to these agents (10 and 50 µmol/L) for 24 hours, respectively. Western blot analysis showed no changes in bcl-2 levels following treatment with either genistein or quercetin at 50 µmol/L (Fig 4B).
View larger version (61K):
[in this window]
[in a new window]
| Fig 3.
Regulation of bcl-2 mRNA expression in JVM-2 cells upon treatment with flavopiridol over a time course of 24 hours. Total cellular RNA (10 µg/lane) of untreated cells (CTRL) and cells cultured in the presence of flavopiridol was hybridized using a digoxigenin-labeled bcl-2 probe. Bcl-2-specific transcripts are shown at 8.5 kb as indicated by the arrow. The lower panel shows rehybridization with a digoxigenin-labeled GAPDH probe.
|
|
View larger version (33K):
[in this window]
[in a new window]
| Fig 4.
(A) Regulation of bcl-2 protein expression in WSU-CLL and I83CLL cells upon treatment with various concentrations of flavopiridol. The cells (1 × 106/mL) were cultured alone (CTRL) or in the presence of flavopiridol (flavo) (200, 400, 800 nmol/L). (B) Exposure of WSU-CLL cells to fludarabine (FAra) (1, 5 µmol/L), genistein (Genist) (50 µmol/L), or quercetin (Querc) (50 µmol/L). Twenty micrograms of protein/lane from cell lysates were loaded on a 12.5% SDS-PAGE gel and electrophoresed. Bcl-2-specific protein was detected using an anti-bcl-2 monoclonal antibody (Dako).
|
|
We also exposed WSU-CLL cells to the purine analogue fludarabine, a conventional therapeutic agent in the treatment of CLL, which has been shown to downregulate bcl-2 in freshly isolated cells from patients with CLL.20 Our results obtained with CLL cell lines revealed no effect with fludarabine at 1 µmol/L, whereas a diminished expression of bcl-2 protein was observed at 5 µmol/L after a 24-hour exposure (Fig 4B).
| |
DISCUSSION |
In the present study we show for the first time that flavopiridol-mediated growth inhibition and induction of apoptosis is associated with a dramatic decline in bcl-2 expression in cell lines representative of B-cell chronic lymphoid malignancies.
Flavopiridol is a recently developed flavone that has been described to be more potent than its structural analogues genistein or quercetin.2 The agent reversibly inhibits tumor cell proliferation2 and induces cell death in noncycling tumor cells such as A549 human lung carcinoma cells.4 Several pathways have been suggested to be activated following administration of flavopiridol. Originally, the drug was reported to inhibit the kinase activity of CDK1 (cdc2) in breast carcinoma cell lines, which is necessary for the cell-cycle progression from G2 to M.3 More recent studies showed that flavopiridol induces G1 arrest with inhibition of CDK2, CDK4, or CDK7.5,21
Bcl-2 has been described as a repressor of apoptosis in many different cell types.22 In most B-CLL cells high levels of both bcl-2 mRNA and protein are documented; however, enhanced expression occurs predominantly in the absence of a t(14; 18) translocation of the gene.12
We report here that flavopiridol, known as an inhibitor of cyclin-dependent kinases, induces a decrease in bcl-2 expression in CLL cell lines. This suggests that flavopiridol-induced cell death involves additional mechanisms of action other than inhibition of cyclin-dependent kinases. Whether the downregulation of bcl-2 is a direct or indirect effect is not known so far. This is presently an area of investigation in our laboratory. Additional experiments with two other flavonoids, genistein23 and quercetin,24 which do not inhibit cyclin-dependent kinases, did not show a significant effect on bcl-2 expression under our experimental conditions at 50 µmol/L. Unexpectedly, at lower concentrations, genistein and quercetin (10 µmol/L) augmented intracellular levels of bcl-2 protein in this system over the same time period (data not shown). In this regard, it is of interest that Liu et al25 previously showed that genistein inhibited the ability of taxol to induce a decline in bcl-2 in a human ovarian tumor cell line system. The mechanisms by which genistein and quercetin augment bcl-2 at lower concentrations is presently under investigation in our laboratory.
Other selective CDK inhibitors such as butyrolactone I26 or roscovitine27,28 have not been reported to have an influence on the expression of bcl-2. It will be important to test whether these specific CDK inhibitors also promote downregulation of bcl-2 to determine if CDK inhibition is a crucial target for this effect. These experiments are presently underway.
In the present study, flavopiridol exhibited significant activity alone in our cell lines. Previous studies in solid tumors have failed to demonstrate significant activity of flavopiridol alone7: however, our recent data suggest that response to single-agent flavopiridol may require a decrease in bcl-2 expression in responding targets, suggesting that downregulation of bcl-2 is an important effect of this drug.29 It is of note that the purine analogue fludarabine, an agent with significant activity in CLL,30,31 has also been shown to downregulate bcl-2 mRNA in freshly isolated cells from CLL patients,20 and in our system, to promote a decline in bcl-2 protein expression in CLL cell lines following a 24-hour exposure to 5 µmol/L.
Dysregulation of apoptosis appears to be involved in the pathogenesis of CLL.32,33 Three purine analogues, fludarabine, pentostatin, and cladribine, potent inducers of apoptosis, are currently of therapeutic benefit in the treatment of CLL.34,35 In addition, the degree of apoptotic cell death induced correlates with disease status. Despite therapy, the relapse rate underscores the need to develop novel strategies for the treatment of this disease. Our data show that flavopiridol exhibits potent activity in these model systems, suggesting that it may be a useful agent in the treatment of chronic lymphoid malignancies.
| |
FOOTNOTES |
Submitted July 17, 1997;
accepted September 16, 1997.
Supported by grants from the Deutsche Forschungsgemeinschaft (Ko 1583/1-1) and the National Institute of Health (CA67823-01).
Address reprint requests to Andrea König, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, PO Box 320, New York, NY 10021.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
REFERENCES |
1.
Suolinna EM,
Lang DR,
Racker E:
Quercetin, an artificial regulator of the high aerobic glycolysis of tumor cells.
J Natl Cancer Inst
53:1515,
1974
2.
Kaur G,
Stetler-Stevenson M,
Sebers S,
Worland P,
Sedlacek H,
Myers C,
Czech J,
Naik R,
Sausville E:
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.
J Natl Cancer Inst
84:1736,
1992[Abstract/Free Full Text]
3.
Losiewicz MD,
Carlson BA,
Kaur G,
Sausville EA,
Worland P:
Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.
Biochem Biophys Res Commun
201:589,
1994[Medline]
[Order article via Infotrieve]
4.
Bible KC,
Kaufmann SH:
Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.
Cancer Res
56:4856,
1996[Abstract/Free Full Text]
5.
Carlson BA,
Dubay MM,
Sausville EA,
Brizuela L,
Worland PJ:
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Cancer Res
56:2973,
1996[Abstract/Free Full Text]
6.
De Azevedo WF Jr,
Mueller-Dieckmann HJ,
Schulze-Gahmen U,
Worland PJ,
Sausville E,
Kim SH:
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
Proc Natl Acad Sci USA
93:2735,
1996[Abstract/Free Full Text]
7. Schwartz GK, Farsi K, Danso D, Dhupar SK, Kelsen D, Spriggs D: The protein kinase C inhibitors UCN-01 and flavopiridol enhance the effect of chemotherapy by promoting apoptosis in gastric and breast cancer cells. Proc Am Soc Clin Oncol 15:501, 1996 (abstr)
8. Senderowicz AM, Headlee D, Stinson S, Lush RM, Figg WD, Pluda J, Sausville EA: A phase I trial of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasm. Proc Am Soc Clin Oncol 16:226a, 1997 (abstr)
9.
Dighiero G,
Travade P,
Chevret S,
Fenaux P,
Chastang C,
Binet JL:
B-cell chronic lymphocytic leukemia: Present status and future directions. French Cooperative Group on CLL. [Review].
Blood
78:1901,
1991[Free Full Text]
10.
Cheson B,
Bennet J,
Rai K,
Grever M,
Kay N,
Schiffer C,
Oken M,
Keating M,
Boldt B,
Kempin S,
Foon K:
Guidelines for the classification of chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group.
Am J Hematol
29:152,
1988[Medline]
[Order article via Infotrieve]
11.
Robertson LE,
Plunkett W,
McConnell K,
Keating MJ,
McDonnell TJ:
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome.
Leukemia
10:456,
1996[Medline]
[Order article via Infotrieve]
12.
Adachi M,
Tefferi A,
Greipp PR,
Kipps TJ,
Tsujimoto Y:
Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia.
J Exp Med
171:559,
1990[Abstract/Free Full Text]
13.
Labalette M,
Queyrel V,
Masy E,
Noel C,
Pruvot FR,
Dessaint JP:
Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients.
Transplantation
59:1714,
1995[Medline]
[Order article via Infotrieve]
14.
Panayiotidis P,
Ganeshaguru K,
Jabbar SA,
Hoffbrand AV:
Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro.
Br J Haematol
85:439,
1993[Medline]
[Order article via Infotrieve]
15.
Melo JV,
Foroni L,
Brito-Babapulle V,
Luzzatto L,
Catovsky D:
The establishment of cell lines from chronic B cell leukaemias: Evidence of leukaemic origin by karyotypic abnormalities and lg gene rearrangement.
Clin Exp Immunol
73:23,
1988[Medline]
[Order article via Infotrieve]
16.
Wendel-Hansen V,
Sallstrom J,
De Campos-Lima PO,
Kjellstrom G,
Sandlund A,
Siegbahn A,
Carlsson M,
Nilsson K,
Rosen A:
Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines.
Leukemia
8:476,
1994[Medline]
[Order article via Infotrieve]
17.
Mohammad RM,
Mohamed AN,
Hamdan MY,
Vo T,
Chen B,
Katato K,
Abubakr YA,
Dugan MC,
Al-Katib A:
Establishment of a human B-CLL xenograft model: Utility as a preclinical therapeutic model.
Leukemia
10:130,
1996[Medline]
[Order article via Infotrieve]
18.
König A,
Menzel T,
Lynen S,
Wrazel L,
Al-Katib A,
Rosen A,
Raveche E,
Gabrilove JL:
Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
Leukemia
11:258,
1997[Medline]
[Order article via Infotrieve]
19.
Gorczyca W,
Gong J,
Ardelt B,
Traganos F,
Darzynkiewicz Z:
The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents.
Cancer Res
53:3186,
1993[Abstract/Free Full Text]
20.
Petersen AJ,
Brown RD,
Gibson J,
Pope B,
Luo X-F,
Schutz L,
Wiley JS,
Joshua DE:
Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
Eur J Haematol
56:213,
1996[Medline]
[Order article via Infotrieve]
21. Carlson BA, Pearlstein RA, Naik RG, Sedlacek H-H, Sausville EA, Worland PJ: Inhibition of CDK2, CDK4, and CDK7 by flavopiridol and structural analogs. Proc Am Assoc Cancer Res 37:424, 1996 (abstr)
22.
Hockenbery D,
Nunez G,
Milliman C,
Schreiber RD,
Korsmeyer SJ:
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.
Nature
348:334,
1990[Medline]
[Order article via Infotrieve]
23.
Matsukawa Y,
Marui N,
Sakai T,
Satomi Y,
Yoshida M,
Matsumoto K,
Nishino H,
Aoike A:
Genistein arrests cell cycle progression at G2-M.
Cancer Res
53:1328,
1993[Abstract/Free Full Text]
24.
Yoshida M,
Sakai T,
Hosokawa N,
Marui N,
Matsumoto K,
Fujioka A,
Nishino H,
Aoike A:
The effect of quercetin on cell cycle progression and growth of human gastric cancer cells.
FEBS Lett
260:10,
1990[Medline]
[Order article via Infotrieve]
25.
Liu Y,
Bhalla K,
Hill C,
Priest DG:
Evidence for involvement of tyrosine phosphorilation in taxol-induced apoptosis in a human ovarian tumor cell line.
Biochem Pharmacol
48:1265,
1994[Medline]
[Order article via Infotrieve]
26.
Kitagawa M,
Okabe T,
Ogino H,
Matsumoto H,
Suzuki-Takahashi I,
Kokubo T,
Higashi H,
Saitoh S,
Taya Y,
Yasuda H,
Ohba Y,
Nishimura S,
Tanaka N,
Okuyama A:
Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase.
Oncogene
8:2425,
1993[Medline]
[Order article via Infotrieve]
27.
de Azevedo WF,
Leclerc S,
Meijer L,
Havlicek L,
Strnad M,
Kim S-H:
Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine.
Eur J Biochem
243:518,
1997[Medline]
[Order article via Infotrieve]
28.
Meijer L,
Borgne A,
Mulner O,
Chong JPJ,
Blow JJ,
Inagaki N,
Inagaki M,
Delcros J-G,
Moulinoux J-P:
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5.
Eur J Biochem
243:527,
1997[Medline]
[Order article via Infotrieve]
29. Schwartz GK, Farsi K, Makhija S, König A, Gabrilove JL, Spriggs D: Sensitivity of tumor cells to the cyclin dependent kinase inhibitor flavopiridol (flavo) correlates with loss of bcl-2 expression. Proc Am Assoc Cancer Res 38:472, 1997 (abstr)
30.
Plunkett W,
Gandhi V,
Huang P,
Robertson LE,
Yang L-Y,
Gregoire V,
Estey E,
Keating MJ:
Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Semin Oncol
20:2,
1993[Medline]
[Order article via Infotrieve]
31.
Catapano CV,
Perrino FW,
Fernandes DJ:
Primer RNA chain termination induced by 9--D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate.
J Biol Chem
268:7179,
1993[Abstract/Free Full Text]
32.
Dancescu M,
Rubio-Trujillo M,
Biron G,
Bron D,
Delespesse G,
Sarfati M:
Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.
J Exp Med
176:1319,
1992[Abstract/Free Full Text]
33.
Hoffbrand AV,
Panayiotidis P,
Reittie J,
Ganeshaguru K:
Autocrine and paracrine growth loops in chronic lymphocytic leukemia. [Review].
Semin Hematol
30:306,
1993[Medline]
[Order article via Infotrieve]
34.
Keating MJ,
O'Brian S,
Kantarjian H,
Robertson LB,
Koller C,
Beran M,
Estey E:
Nucleoside analogs in the treatment of chronic lymphocytic leukemia. [Review].
Leuk Lymphoma
10:139,
1993
35.
Johnson SA:
Purine analogues in the management of lymphoproliferative dioseases. [Review].
Clin Oncol (R Coll Radiol)
8:289,
1996[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Takada, G. Sethi, B. Sung, and B. B. Aggarwal
Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid Cells
Mol. Pharmacol.,
May 1, 2008;
73(5):
1549 - 1557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, T. S. Lin, J. T. Dalton, D. Wu, M. A. Phelps, B. Fischer, M. Moran, K. A. Blum, B. Rovin, M. Brooker-McEldowney, et al.
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
Blood,
January 15, 2007;
109(2):
399 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Palacios, R. Yerbes, and A. Lopez-Rivas
Flavopiridol Induces Cellular FLICE-Inhibitory Protein Degradation by the Proteasome and Promotes TRAIL-Induced Early Signaling and Apoptosis in Breast Tumor Cells.
Cancer Res.,
September 1, 2006;
66(17):
8858 - 8869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. I. Shapiro
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
J. Clin. Oncol.,
April 10, 2006;
24(11):
1770 - 1783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. K. Lee, C. R. Isham, S. H. Kaufman, and K. C. Bible
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy
Mol. Cancer Ther.,
January 1, 2006;
5(1):
138 - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Whitlock, M. Krailo, J. M. Reid, S. L. Ruben, M. M. Ames, W. Owen, and G. Reaman
Phase I Clinical and Pharmacokinetic Study of Flavopiridol in Children With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol.,
December 20, 2005;
23(36):
9179 - 9186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Schwartz and M. A. Shah
Targeting the Cell Cycle: A New Approach to Cancer Therapy
J. Clin. Oncol.,
December 20, 2005;
23(36):
9408 - 9421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Bible, J. L. Lensing, S. A. Nelson, Y. K. Lee, J. M. Reid, M. M. Ames, C. R. Isham, J. Piens, S. L. Rubin, J. Rubin, et al.
Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points
Clin. Cancer Res.,
August 15, 2005;
11(16):
5935 - 5941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Schwartz
Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy
J. Clin. Oncol.,
July 10, 2005;
23(20):
4499 - 4508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Brown
Chronic Lymphocytic Leukemia: A Niche for Flavopiridol?
Clin. Cancer Res.,
June 1, 2005;
11(11):
3971 - 3973.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, B. L. Peterson, J. Gabrilove, O. M. Odenike, M. R. Grever, K. Rai, R. A. Larson, and the Cancer and Leukemia Group B
Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805
Clin. Cancer Res.,
June 1, 2005;
11(11):
4176 - 4181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Richard, D. Matthews, W. Duivenvoorden, J. Yau, P. S. Wright, and J. P.H. Th'ng
Flavopiridol Sensitivity of Cancer Cells Isolated from Ascites and Pleural Fluids
Clin. Cancer Res.,
May 1, 2005;
11(9):
3523 - 3529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Puppo, S. Pastorino, G. Melillo, A. Pezzolo, L. Varesio, and M. C. Bosco
Induction of Apoptosis by Flavopiridol in Human Neuroblastoma Cells Is Enhanced under Hypoxia and Associated With N-myc Proto-oncogene Down-Regulation
Clin. Cancer Res.,
December 15, 2004;
10(24):
8704 - 8719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. N. Demidenko and M. V. Blagosklonny
Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor
Cancer Res.,
May 15, 2004;
64(10):
3653 - 3660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takada and B. B. Aggarwal
Flavopiridol Inhibits NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of I{kappa}B{alpha} Kinase and p65 Phosphorylation: ABROGATION OF CYCLIN D1, CYCLOOXYGENASE-2, AND MATRIX METALLOPROTEASE-9
J. Biol. Chem.,
February 6, 2004;
279(6):
4750 - 4759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Aklilu, H. L. Kindler, R. C. Donehower, S. Mani, and E. E. Vokes
Phase II study of flavopiridol in patients with advanced colorectal cancer
Ann. Onc.,
August 1, 2003;
14(8):
1270 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bevilacqua, M. C. Ceriani, G. Canti, L. Asnaghi, R. Gherzi, G. Brewer, L. Papucci, N. Schiavone, S. Capaccioli, and A. Nicolin
Bcl-2 Protein Is Required for the Adenine/Uridine-rich Element (ARE)-dependent Degradation of Its Own Messenger
J. Biol. Chem.,
June 20, 2003;
278(26):
23451 - 23459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Kouroukis, A. Belch, M. Crump, E. Eisenhauer, R. D. Gascoyne, R. Meyer, R. Lohmann, P. Lopez, J. Powers, R. Turner, et al.
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol.,
May 1, 2003;
21(9):
1740 - 1745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wittmann, P. Bali, S. Donapaty, R. Nimmanapalli, F. Guo, H. Yamaguchi, M. Huang, R. Jove, H. G. Wang, and K. Bhalla
Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis
Cancer Res.,
January 1, 2003;
63(1):
93 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ma, W. D. Cress, and E. B. Haura
Flavopiridol-induced Apoptosis Is Mediated through Up-Regulation of E2F1 and Repression of Mcl-1
Mol. Cancer Ther.,
January 1, 2003;
2(1):
73 - 81.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas
Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial
Clin. Cancer Res.,
January 1, 2003;
9(1):
307 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gojo, B. Zhang, and R. G. Fenton
The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1
Clin. Cancer Res.,
November 1, 2002;
8(11):
3527 - 3538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Tan, D. Headlee, R. Messmann, E. A. Sausville, S. G. Arbuck, A. J. Murgo, G. Melillo, S. Zhai, W. D. Figg, S. M. Swain, et al.
Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
J. Clin. Oncol.,
October 1, 2002;
20(19):
4074 - 4082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. A. Elsayed and E. A. Sausville
Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins
Oncologist,
December 1, 2001;
6(6):
517 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Schwartz, D. Ilson, L. Saltz, E. O'Reilly, W. Tong, P. Maslak, J. Werner, P. Perkins, M. Stoltz, and D. Kelsen
Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma
J. Clin. Oncol.,
April 1, 2001;
19(7):
1985 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Bible, R. H. Bible Jr., T. J. Kottke, P. A. Svingen, K. Xu, Y.-P. Pang, E. Hajdu, and S. H. Kaufmann
Flavopiridol Binds to Duplex DNA
Cancer Res.,
May 1, 2000;
60(9):
2419 - 2428.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. M. Senderowicz and E. A. Sausville
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
J Natl Cancer Inst,
March 1, 2000;
92(5):
376 - 387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Bible, S. A. Boerner, K. Kirkland, K. L. Anderl, D. Bartelt Jr., P. A. Svingen, T. J. Kottke, Y. K. Lee, S. Eckdahl, P. G. Stalboerger, et al.
Characterization of an Ovarian Carcinoma Cell Line Resistant to Cisplatin and Flavopiridol
Clin. Cancer Res.,
February 1, 2000;
6(2):
661 - 670.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W. M. Stadler, N. J. Vogelzang, R. Amato, J. Sosman, D. Taber, D. Liebowitz, and E. E. Vokes
Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study
J. Clin. Oncol.,
January 14, 2000;
18(2):
371 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, M. Bhuiyan, S. Alhasan, A. M. Senderowicz, and F. H. Sarkar
Induction of Apoptosis and Inhibition of c-erbB-2 in Breast Cancer Cells by Flavopiridol
Clin. Cancer Res.,
January 1, 2000;
6(1):
223 - 229.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. I. Shapiro, D. A. Koestner, C. B. Matranga, and B. J. Rollins
Flavopiridol Induces Cell Cycle Arrest and p53-independent Apoptosis in Non-Small Cell Lung Cancer Cell Lines
Clin. Cancer Res.,
October 1, 1999;
5(10):
2925 - 2938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ruef, A. S. Meshel, Z. Hu, C. Horaist, C. A. Ballinger, L. J. Thompson, V. D. Subbarao, J. A. Dumont, and C. Patterson
Flavopiridol Inhibits Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo After Carotid Injury in the Rat
Circulation,
August 10, 1999;
100(6):
659 - 665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Kottke, A. L. Blajeski, L. M. Martins, P. W. Mesner Jr., N. E. Davidson, W. C. Earnshaw, D. K. Armstrong, and S. H. Kaufmann
Comparison of Paclitaxel-, 5-Fluoro-2'-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis. EVIDENCE FOR EGF-INDUCED ANOIKIS
J. Biol. Chem.,
May 28, 1999;
274(22):
15927 - 15936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, C. Shinn, J. K. Waselenko, E. J. Fuchs, T. A. Lehman, P. L. Nguyen, I. W. Flinn, L. F. Diehl, E. Sausville, and M. R. Grever
Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Dependence on Functional p53
Blood,
November 15, 1998;
92(10):
3804 - 3816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mohr, T. S. McCormick, and E. G. Lapetina
Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: Dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059
PNAS,
April 28, 1998;
95(9):
5045 - 5050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. V. Achenbach, R. Muller, and E. P. Slater
Bcl-2 Independence of Flavopiridol-induced Apoptosis. MITOCHONDRIAL DEPOLARIZATION IN THE ABSENCE OF CYTOCHROME c RELEASE
J. Biol. Chem.,
October 6, 2000;
275(41):
32089 - 32097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract